| Literature DB >> 31428613 |
Camila Felix de Lima Fernandes1, Rebeca Piatniczka Iglesia1, Maria Isabel Melo-Escobar1, Mariana Brandão Prado1, Marilene Hohmuth Lopes1.
Abstract
Pluripotency is orchestrated by distinct players and chaperones and their partners have emerged as pivotal molecules in proteostasis control to maintain stemness. The proteostasis network consists of diverse interconnected pathways that function dynamically according to the needs of the cell to quality control and maintain protein homeostasis. The proteostasis machinery of pluripotent stem cells (PSCs) is finely adjusted in response to distinct stimuli during cell fate commitment to determine successful organism development. Growing evidence has shown different classes of chaperones regulating crucial cellular processes in PSCs. Histones chaperones promote proper nucleosome assembly and modulate the epigenetic regulation of factors involved in PSCs' rapid turnover from pluripotency to differentiation. The life cycle of pluripotency proteins from synthesis and folding, transport and degradation is finely regulated by chaperones and co-factors either to maintain the stemness status or to cell fate commitment. Here, we summarize current knowledge of the chaperone network that govern stemness and present the versatile role of chaperones in stem cells resilience. Elucidation of the intricate regulation of pluripotency, dissecting in detail molecular determinants and drivers, is fundamental to understanding the properties of stem cells in order to provide a reliable foundation for biomedical research and regenerative medicine.Entities:
Keywords: chaperone; histone; pluripotency; stem cells; stemness
Year: 2019 PMID: 31428613 PMCID: PMC6688531 DOI: 10.3389/fcell.2019.00150
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Chaperome regulation and proteostasis network in ESCs. Scheme shows molecular pathways ranging from gene transcription to protein degradation involved in pluripotency control. The interconnected self-regulating nuclear core formed by OCT4, SOX2, and NANOG is essential for the maintenance of stemness. (A) In mESCs, HIRA is abundantly associated with promoter regions of developmentally regulated genes, being responsible for H3.3 deposition and enrichment, co-localizing with the transcriptional active form of methylated H3K4. Chaperone protein HSP90 and its partner HOP are engaged in key intracellular signaling pathways in PSCs, including LIF/JAK/STAT3. HSP90-HOP complex participates actively in the phosphorylation and translocation of STAT3 to the nucleus, leading to the transcription of pluripotency core factors. HSPs complexes can also prevent OCT4 degradation by proteasome. Proteasome-related proteins, such as WWP2, acting as E3 ligases or by other mechanisms, lead to TFs degradation by UPS, controlling its levels and maintaining proteostasis balance in these cells. (B) In hESCs, FGF2, used to culture these cells, activate the signaling cascade mediated by Ras/MEK/ERK and p-ERK translocation to the nucleus, favoring the expression of pluripotency genes. Acetylation of H3K56 by ASF1 regulates de expression of pluripotency genes. Unlike differentiated cells, HSP70 is present in the cell surface of hESCs, colocalizing with known pluripotency markers such as SSEA3 and SSEA4. Upregulation of the protein FOXO4 leads to the increase of the 19S proteasome subunit PSMD11, resulting in more functional proteasome subunits formed and increased activity of the UPS. The TF NRF2 upregulation is also associated with the increase in functional proteasome subunits, and also is associated with expression of the pluripotency TFs OCT4, SOX2, and NANOG.
FIGURE 2Chaperome regulation and proteostasis network in human iPSCs. TGF-β/Activin A and FGF2/Ras/MEK/ERK pathways are required for the maintenance of iPSCs in culture conditions. The histone chaperone NPM2 binds to the histone variants TH2A and TH2 and improve the reprogramming of human fibroblast into iPSCs modulated by OCT4, SOX2, KLF4 and c-MYC, generating more naïve human iPSCs compared to factors induction alone. ASF1a histone chaperone upregulation, together with OCT4, also has an important role in reprogramming of human fibroblast. Cell fate commitment (highlighted in light brown) involves the induction of different specific pathways that can lead to differentiation into various cell types. The molecular chaperone HSP90β physically binds to HNF4A and control the protein turnover of these client, modulating differentiation of iPSCs to endoderm-derived hepatic progenitor cells. Downregulation (represented as a red glow around the molecule) of the proteasome-related protein PSMD14, a 26S proteasome subunit, impairs the deubiquitylation of OCT4, leading to its degradation in the proteasome and impairment of pluripotency.
Major classes of histone chaperones and their function in stemness of different PSCs models.
| HIRA | Highly expressed in the promoters of developmentally regulated genes in mESCs | ||
| Differentiation of mESCs in hemogenic endothelium | |||
| Pluripotency maintenance of hESCs, promoting isocitrate dehydrogenase genes (IDHs) transcription | |||
| Developmental reprogramming – deposition of paternal core histone and reactivation of maternal genome in mice | |||
| DAXX/ATX | Telomeric deposition (immortalization) in mESCs | ||
| ASF1 | Differentiation during murine early embryogenesis and gonad development | ||
| Pluripotency maintenance in hESCs | |||
| Pluripotency maintenance in mESCs | |||
| Reprogramming of human fibroblasts into iPSCs | |||
| CAF-1 | Early developmental arrest and early gastrulation of mESCs | ||
| Reprogramming of mouse fibroblasts into iPSCs | |||
| Pluripotency maintenance during blastomeric stage in mice | |||
| FACT | Proliferation and neural differentiation of mESCs | ||
| Associates with OCT4 and regulates mESCs pluripotency Survival during early blastocyst stage of mESCs | |||
| Reprogramming into iPSCs | |||
| HMGA2 | mESCs specific DNA repair mechanism. | ||
| NPM2 | Reprogramming of human fibroblast into iPSCs; Improvement of murine cells reprogramming using only KLF4 and OCT4 | ||
| NPM3 | Proliferation of mESCs | ||
| SPT6 | Pluripotency maintenance of mESCs | ||
| SET | SETα | Proliferation of hESCs | |
| SETβSETP | Differentiation of hESCs | ||
List of chaperones and proteasome-related proteins and their function associated to protein homeostasis and pluripotency control in different PSCs models.
| Chaperome | HSP90 | Pluripotency maintenance and mesoderm differentiation of mESCs | |
| STAT3 translocation to nucleus and NANOG negative regulation in mESC | |||
| Endoderm differentiation of iPSCs | |||
| HOP | STAT3 expression and phosphorylation and NANOG expression in mESCs | ||
| Murine embryonic survival | |||
| HSP70 | Surface marker of pluripotency in hESCs | ||
| Differentiation of mESCs | |||
| Differentiation and survival of iPSCs | |||
| Early differentiation of hESCs and mESCs | |||
| HSP60 | OCT4 expression, proliferation, self-renewal and survival of mESCs | ||
| HSP40 | mESCs differentiation into smooth muscle cells Endoderm differentiation marker | ||
| HSP27 | NANOG inactivation and neuronal differentiation of human placenta-derived cells | ||
| Proteasome related | PSMD14 | OCT4 regulation in mESCs and iPSCs | |
| FBXW7 | Negative regulation of c-MYC protein stability in mESCs and iPSCs | ||
| NRF2 | Pluripotency maintenance in hESCs and iPSCs | ||
| PSMD11 | Functional proteasome complexes formation in hESC and iPSC | ||
| F0X04 | PSMD11 expression regulator in hESCs and iPSC | ||
| L1TD1 | Downregulation leads to decrease in SOX2 and PSMD11 of hESC | ||
| C0PS2 | NANOG protein stability regulator of mESCs | ||
| WWP2 | Promotes OCT4 and SOX2 proteasome degradation in mESCs | ||
| SET7 | SOX2 methylation and proteasome degradation promotion in mESCs Transcriptional activity inhibition in mESCs | ||
| AKT1 | SOX2 phosphorylation and proteasome degradation prevention in mESCs | ||
| UBR5 | Proteostasis machinery regulator in hESCs and iPSCs | ||
| FBXW8 | Polyubiquitynates NANOG and mESCs | ||
| USP21 | NANOG protein stabilization in mESCs and hESCs | ||
| USP26 | NANOG and SOX2 genes inhibition in hESCs | ||